0001104659-24-119970.txt : 20241118 0001104659-24-119970.hdr.sgml : 20241118 20241118080352 ACCESSION NUMBER: 0001104659-24-119970 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20241118 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241118 DATE AS OF CHANGE: 20241118 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SELECT MEDICAL HOLDINGS CORP CENTRAL INDEX KEY: 0001320414 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOSPITALS [8060] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34465 FILM NUMBER: 241469796 BUSINESS ADDRESS: STREET 1: C/O SELECT MEDICAL CORP STREET 2: 4714 GETTYSBURG RD CITY: MECHANICSBURG STATE: PA ZIP: 17055 BUSINESS PHONE: 717-972-1100 MAIL ADDRESS: STREET 1: C/O SELECT MEDICAL CORP STREET 2: 4714 GETTYSBURG RD CITY: MECHANICSBURG STATE: PA ZIP: 17055 8-K 1 tm2428673d1_8k.htm FORM 8-K
false 0001320414 0001320414 2024-11-18 2024-11-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

 

FORM 8-K

 

current report

 

Pursuant to Section 13 or 15(d) of the

 

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 18, 2024

 

 

 

SELECT MEDICAL HOLDINGS CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

Delaware  001-34465  20-1764048
(State or other jurisdiction of
Incorporation)
  (Commission File
Number)
  (I.R.S. Employer
Identification No.)

 

 

 

4714 Gettysburg Road, P.O. Box 2034

Mechanicsburg, PA 17055

(Address of principal executive offices)  (Zip Code)

 

(717) 972-1100

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.001 per share SEM New York Stock Exchange (NYSE)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 7.01Regulation FD Disclosure  

 

Select Medical Corporation (the “Company”), a wholly owned subsidiary of Select Medical Holdings Corporation, intends to offer $850 million in aggregate principal amount of senior notes due 2032. The senior notes will be issued by the Company and will be unconditionally guaranteed by certain of the Company’s subsidiaries.

 

The Company intends to use the net proceeds of the offering, together with the proceeds from a new incremental term loan and cash on hand, to repay in full the term loan currently outstanding under its existing credit agreement and to redeem all of its outstanding 6.250% senior notes due 2026.

 

In connection with the repayment, the Company intends to amend its existing senior secured credit facilities in order to, among other things:

 

·establish a new incremental term loan under the Company’s existing senior secured credit agreement in the aggregate principal amount of $750 million;

 

·extend the tenor of our revolving credit facility to five years from the date the senior notes are issued;

 

·provide for an incremental revolving commitment in an aggregate amount of $50 million; and

 

·make certain other changes to the credit agreement.

 

The terms of the amendments to the Company’s senior secured credit facilities are under discussion. Accordingly, their definitive terms may vary from those described above.

 

The senior notes will be issued through a private placement and resold by initial purchasers to qualified institutional buyers under Rule 144A of the Securities Act of 1933, as amended, and Regulation S. The senior notes will not be registered under the Securities Act and cannot be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This does not constitute an offer to sell or the solicitation of an offer to buy any security in any jurisdiction in which such offer or sale would be unlawful.

 

Cautionary Note Regarding Forward-Looking Statements

 

Except for historical information, all other information in this Form 8-K consists of forward-looking statements. These forward-looking statements involve a number of risks, uncertainties and other factors, including the contemplated size of a note offering, possible completion of a note offering, the prospective impact of a note offering, plans to repay certain indebtedness (including the terms and success of such repayment), which may cause the actual results to be materially different from those expressed or implied in the forward-looking statements. Other important factors that could cause the statements made in this Form 8-K or the actual results of operations or financial condition of the Company to differ include, without limitation, that the note offering is subject to market conditions and a number of other conditions and approvals and the final terms may vary substantially as a result of market and other conditions. There can be no assurance that the note offering will be completed as described herein or at all. Other important factors are discussed under the caption “Forward-Looking Statements” in the Company’s Form 10-Q Quarterly Report for the quarter ended September 30, 2024 and in subsequent filings made prior to or after the date hereof. The Company does not intend to review or revise any particular forward-looking statement in light of future events.

 

 

 

 

Certain Information

 

Attached as Exhibit 99.1 to the report are selected portions of information from an offering memorandum that the Company expects to disclose to investors in connection with the proposed private placement. There can be no assurance that the placement will be completed as described in the offering memorandum or at all.

 

The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

 

Item 8.01Other Events

 

On November 18, 2024, Select Medical Holdings Corporation issued a press release announcing the Company had commenced an offering of $850 million aggregate principal amount of senior notes due 2032. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit Number   Description
     
*99.1   Selected portions of information from an offering memorandum that the Company expects to disclose to investors in connection with its proposed private placement.
99.2   Press Release, dated November 18, 2024, announcing the offering of senior notes due 2032.
104   Cover Page Interactive Data File (embedded with the Inline XBRL)
     

* The information in this Item 9.01 shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  SELECT MEDICAL HOLDINGS CORPORATION
   
   
Date: November 18, 2024 By: /s/ Michael E. Tarvin
    Michael E. Tarvin
    Senior Executive Vice President, General Counsel and Secretary

 

 

 

 

EX-99.1 2 tm2428673d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

Cautionary Note Regarding Forward-Looking Statements

 

This offering memorandum contains forward-looking statements within the meaning of the federal securities laws. Statements that are not historical facts, including statements about our beliefs and expectations, are forward-looking statements. Forward-looking statements include statements preceded by, followed by or that include the words “may,” “could,” “would,” “should,” “believe,” “expect,” “anticipate,” “plan,” “target,” “estimate,” “project,” “intend” and similar expressions. These statements include, among others, statements regarding our expected business outlook, anticipated financial and operating results, our business strategy and means to implement our strategy, our objectives, the amount and timing of capital expenditures, the likelihood of our success in expanding our business, financing plans, budgets, working capital needs and sources of liquidity.

 

Forward-looking statements are only predictions and are not guarantees of performance. These statements are based on our management’s beliefs and assumptions, which in turn are based on currently available information. Important assumptions relating to the forward-looking statements include, among others, assumptions regarding our services, the expansion of our services, competitive conditions and general economic conditions. These assumptions could prove inaccurate. Forward-looking statements also involve known and unknown risks and uncertainties, which could cause actual results to differ materially from those contained in any forward-looking statement. Many of these factors are beyond our ability to control or predict. Such factors include, but are not limited to, the following:

 

·changes in government reimbursement for our services and/or new payment policies may result in a reduction in revenue, an increase in costs, and a reduction in profitability;

 

·adverse economic conditions including an inflationary environment could cause us to continue to experience increases in the prices of labor and other costs of doing business resulting in a negative impact on our business, operating results, cash flows, and financial condition;

 

·shortages in qualified nurses, therapists, physicians, or other licensed providers, and/or the inability to attract or retain qualified healthcare professionals could limit our ability to staff our facilities;

 

·shortages in qualified health professionals could cause us to increase our dependence on contract labor, increase our efforts to recruit and train new employees, and expand upon our initiatives to retain existing staff, which could increase our operating costs significantly;

 

·public threats such as a global pandemic, or widespread outbreak of an infectious disease, similar to the COVID-19 pandemic, could negatively impact patient volumes and revenues, increase labor and other operating costs, disrupt global financial markets, and/or further legislative and regulatory actions which impact healthcare providers, including actions that may impact the Medicare program;

 

·the failure of our Medicare-certified long term care hospitals or inpatient rehabilitation facilities to maintain their Medicare certifications may cause our revenue and profitability to decline;

 

·the failure of our Medicare-certified long term care hospitals and inpatient rehabilitation facilities operated as “hospitals within hospitals” to qualify as hospitals separate from their host hospitals may cause our revenue and profitability to decline;

 

·a government investigation or assertion that we have violated applicable regulations may result in sanctions or reputational harm and increased costs;

 

·acquisitions or joint ventures may prove difficult or unsuccessful, use significant resources, or expose us to unforeseen liabilities;

 

·our plans and expectations related to our acquisitions and our ability to realize anticipated synergies;

 

·failure to complete or achieve some or all the expected benefits of the potential separation of Concentra;

 

·private third-party payors for our services may adopt payment policies that could limit our future revenue and profitability;

 

 

 

 

·the failure to maintain established relationships with the physicians in the areas we serve could reduce our revenue and profitability;

 

·competition may limit our ability to grow and result in a decrease in our revenue and profitability;

 

·the loss of key members of our management team could significantly disrupt our operations;

 

·the effect of claims asserted against us could subject us to substantial uninsured liabilities;

 

·a security breach of our or our third-party vendors’ information technology systems may subject us to potential legal and reputational harm and may result in a violation of the Health Insurance Portability and Accountability Act of 1996 or the Health Information Technology for Economic and Clinical Health Act; and

 

·other factors discussed under the heading “Risk factors” herein or incorporated by reference from our annual report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 22, 2024.

 

Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements, whether as a result of any new information, future events or otherwise. You should not place undue reliance on our forward-looking statements. Although we believe that the expectations reflected in forward-looking statements are reasonable, we cannot guarantee future results or performance.

 

 

 

 

SUMMARY UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL INFORMATION

 

The summary unaudited pro forma consolidated financial data below has been derived from our unaudited pro forma consolidated financial information included in the section of this offering memorandum entitled “Unaudited Pro Forma Consolidated Financial Information.” The unaudited pro forma consolidated financial information has been derived from our historical unaudited condensed consolidated statement of operations for the nine months ended September 30, 2024, our historical audited consolidated statement of operations for the year ended December 31, 2023, and our historical unaudited condensed consolidated balance sheet at September 30, 2024.

 

The unaudited pro forma consolidated financial data below is only a summary and should be read in conjunction with the section of this offering memorandum entitled “Unaudited Pro Forma Consolidated Financial Information.” The unaudited pro forma consolidated financial data is based upon available information and assumptions that we believe are reasonable and supportable. The summary unaudited pro forma consolidated financial data is for illustrative and informational purposes only. The summary unaudited pro forma consolidated financial data may not necessarily reflect what our financial condition, results of operations or cash flows would have been had we completed the divestiture of our Concentra segment during the periods presented. In addition, the summary unaudited pro forma consolidated financial data may not necessarily reflect what our financial condition, results of operations and cash flows may be in the future.

 

Pro Forma Consolidated Statement of Operations Data

 

   For the Nine Months Ended
September 30,
   Year ended December 31, 
(Dollars in thousands)  2024   2023 
Revenue  $3,874,541   $4,825,977 
Costs and expenses:          
Cost of services, exclusive of depreciation and amortization   3,379,931    4,254,369 
General and administrative   144,103    170,193 
Depreciation and amortization   106,583    135,691 
Total costs and expenses   3,630,617    4,560,253 
Other operating income   3,300    1,518 
Income from operations   247,224    267,242 
Other income and expense:          
Loss on early retirement of debt       (35,353)
Equity in earnings of unconsolidated subsidiaries   53,481    41,339 
Interest (expense) income   (63,274)   18,454 
Income before income taxes   237,431    291,682 
Income tax expense   61,928    69,568 
Net income   175,503    222,114 
Less: Net income attributable to non-controlling interests   51,306    51,444 
Net income attributable to Holdings  $124,197   $170,670 

 

Pro Forma Consolidated Balance Sheet Data

 

     
(Dollars in thousands)  As of September 30, 2024 
Total assets  $5,510,682 
Total liabilities  $3,511,470 
Total equity  $1,986,879 

 

 

 

 

Pro Forma Credit Statistics

 

(Dollars in thousands) 

As of or for the Twelve
Months Ended September 30, 2024(1)

 
Cash interest expense(2)  $104,844 
Total debt(3)  $1,658,721 
Net debt(4)  $1,631,399 
Net senior secured debt(5)  $732,678 
Ratio of Pro Forma Adjusted EBITDA to Pro Forma cash interest expense(6)   4.83x
Ratio of net senior secured debt to Pro Forma Adjusted EBITDA(6)   1.45x
Ratio of net debt to Pro Forma Adjusted EBITDA(6)   3.22x

 

 

(1) As of September 30, 2024, after giving pro forma effect to the incurrence of indebtedness in an aggregate principal amount equal to $1,600.00 million pursuant to the Refinancing Transactions.

 

(2) Calculated to give pro forma effect to the interest expense on the approximately $1,600.0 million of indebtedness expected to be incurred in connection with the Refinancing Transactions, as well as existing Other Debt of $48.7 million, as if such indebtedness had been incurred as of October 1, 2023 at an estimated weighted average interest rate of approximately 6.4%, excluding debt issuance costs and original issue discount. A variance of 1/8% of the weighted average interest rate estimate would result in a $2.0 million change in annual cash interest expense associated with the $1,600.0 million of indebtedness expected to be incurred.

 

(3) Consists of $1,600.0 million of indebtedness (including the Notes offered hereby) expected to be incurred pursuant to the Refinancing Transactions, $10.0 million of indebtedness outstanding under our revolving credit facility, and $48.7 million of indebtedness comprised primarily of notes payable, insurance financing arrangements and finance leases.

 

(4) Consists of total debt principal less pro forma cash of approximately $27.3 million as of September 30, 2024.

 

(5) Consists of total senior secured debt principal less pro forma cash of approximately $27.3 million as of September 30, 2024.

 

(6) Pro Forma Adjusted EBITDA for the trailing twelve months ended September 30, 2024, is $506.2 million which is calculated as Historical Select Medical Holdings Corporation trailing twelve month Adjusted EBITDA of $873.8 million less Concentra Adjusted EBITDA of $367.6 million.

 

Other Pro Forma Data (Non-GAAP)

 

   Nine Months Ended September 30   Year Ended December 31, 
(Dollars in thousands)  2024   2023 
Pro Forma Adjusted EBITDA(1)  $394,402   $446,091 
Pro Forma Adjusted EBITDA margin(1)   10.2%   9.2%

 

 

(1)We believe that the presentation of Pro Forma Adjusted EBITDA and Pro Forma Adjusted EBITDA margin, as defined herein, are important to investors because Pro Forma Adjusted EBITDA and Pro Forma Adjusted EBITDA margin, or equivalents thereto, are commonly used as an analytical indicator of performance by investors within the healthcare industry. Pro Forma Adjusted EBITDA and Pro Forma Adjusted EBITDA margin are used by management to evaluate financial performance of, and determine resource allocation for, each of our operating segments. However, Pro Forma Adjusted EBITDA and Pro Forma Adjusted EBITDA margin are not measures of financial performance under GAAP. Items excluded from Pro Forma Adjusted EBITDA and Pro Forma Adjusted EBITDA margin are significant components in understanding and assessing financial performance. Pro Forma Adjusted EBITDA and Pro Forma Adjusted EBITDA margin should not be considered in isolation, or as an alternative to, or substitute for, net income, net income margin, income from operations, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because Pro Forma Adjusted EBITDA and Pro Forma Adjusted EBITDA margin are not measurements determined in accordance with GAAP and are thus susceptible to varying definitions, Pro Forma Adjusted EBITDA and Pro Forma Adjusted EBITDA margin as presented may not be comparable to other similarly titled measures of other companies.

 

 

 

 

The following table reconciles Pro Forma Adjusted EBITDA and Pro Forma Adjusted EBITDA margin to Pro Forma Net income and should be referenced when we discuss Pro Forma Adjusted EBITDA and Pro Forma Adjusted EBITDA margin. For a reconciliation of Pro Forma Net income to Net income, see “Unaudited Pro Forma Consolidated Financial Information.”

 

   Nine Months Ended September 30,   Year Ended December 31, 
(Dollars in thousands)  2024   2023 
Reconciliation of Pro Forma Adjusted EBITDA to Pro Forma Net income          
Pro Forma Net Income  $175,503   $222,114 
Pro Forma Income tax expense   61,928    69,568 
Pro Forma Interest expense   63,274    (18,454)
Pro Forma Equity in losses of unconsolidated subsidiaries   (53,481)   (41,339)
Pro Forma Loss on early retirement of debt       35,353 
Pro Forma Income from Operations   247,224    267,242 
Pro Forma Stock compensation expense   38,899    43,158 
Pro Forma Depreciation and amortization   106,583    135,691 
Pro Forma Separation transaction costs   1,696     
Pro Forma Adjusted EBITDA  $394,402   $446,091 
Pro Forma Adjusted EBITDA margin   10.2%   9.2%
Pro Forma Net Income Margin   4.5%   4.6%

 

 

 

 

CAPITALIZATION

 

The following table sets forth our consolidated cash and cash equivalents and capitalization as of September 30, 2024:

 

·on a pro forma basis as derived from our historical audited consolidated financial statements incorporated by reference into this offering memorandum and giving effect to the Separation; and

 

·on a pro forma as adjusted basis to give effect to the Separation and to the Refinancing Transactions.

 

The cash and capitalization information in the following table may not necessarily reflect what our cash and capitalization would have been had we completed the Separation as of September 30, 2024. In addition, the cash and capitalization information in the following table may not necessarily reflect what our cash and capitalization may be in the future. The pro forma information set forth in the table below is illustrative only and will adjust based on the actual terms of this offering determined at the time of the pricing of this offering.

 

The following table should be read in conjunction with the sections of this offering memorandum entitled “Summary Unaudited Pro Forma Consolidated Financial Data,” “Use of Proceeds” and “Unaudited Pro Forma Consolidated Financial Information” as well as our historical audited consolidated financial statements included elsewhere in this offering memorandum.

 

   As of September 30, 2024 
(Dollars and share amounts in thousands) (unaudited)  Pro Forma   Pro Forma
As Adjusted
 
Cash and cash equivalents  $54,646   $27,322 
Debt:          
Existing Select Term Loan   372,982     
New Select Term Loan       750,000 
Senior secured revolving facility(1)   10,000    10,000 
Total senior secured principal  $382,982   $760,000 
2026 Notes   1,225,000     
Notes offered hereby(2)       850,000 
Other debt(3)   48,721    48,721 
Total debt principal outstanding  $1,656,703   $1,658,721 
Unamortized discount   9,346    (1,875)
Unamortized debt issuance costs   (6,654)   (24,775)
Total debt  $1,659,395   $1,632,071 
           
Total stockholders’ equity   1,688,127    1,688,127 
Total capitalization   3,347,522    3,320,198 
           
Total net debt principal outstanding   1,602,057    1,631,399 
Total net senior secured principal   328,336    732,678 

 

 

(1)            The revolving loan under our senior secured credit facilities provides for borrowings of up to $600.0 million of which $546.6 million was available as of September 30, 2024, for working capital and general corporate purposes (after given effect to the Refinancing Transactions and to $43.4 million of outstanding letters of credit at September 30, 2024).

 

(2)            Represents the aggregate principal amount of the notes being offered and does not reflect initial purchaser discounts and debt issuance costs.

 

(3)            Other debt consists primarily of borrowings to finance insurance programs, indebtedness to sellers of acquired businesses and other miscellaneous borrowings.

 

 

 

 

UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL INFORMATION

 

The following unaudited pro forma consolidated statements of operations for the nine months ended September 30, 2024, and for the year ended December 31, 2023, are presented as if the Separation and the Refinancing Transactions occurred as of January 1, 2023. The adjustments in the “Transaction Accounting Adjustments” column in the unaudited pro forma condensed consolidated statements of operations for the nine months ended September 30, 2024, and for the year ended December 31, 2023, give effect to the Separation as if it occurred as of January 1, 2023. The adjustments in the “Refinancing Transaction Adjustments” column in the unaudited pro forma condensed consolidated statements of operations for the nine months ended September 30, 2024, and for the year ended December 31, 2023, give effect to the Refinancing Transactions as if the Refinancing Transactions occurred as of January 1, 2023. The following unaudited pro forma consolidated balance sheet as of September 30, 2024 is presented as if Separation and the Refinancing Transactions occurred on September 30, 2024.

 

The following unaudited pro forma consolidated financial information has been derived from our historical consolidated financial statements as of and for the year ended December 31, 2023 and the interim unaudited period ended September 30, 2024. The unaudited pro forma consolidated financial information and the accompanying notes should be read in conjunction with (i) the audited consolidated financial statements, the accompanying notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the year ended December 31, 2023, and (ii) the unaudited consolidated financial statements, the accompanying notes, and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024.

 

The following unaudited pro forma financial information is based on information currently available, including certain assumptions and estimates. They are intended for informational purposes only, and do not purport to represent what our financial position and results of operations actually would have been had the Separation occurred on the dates indicated, or to project our financial position or results of operations for any future date or period. The adjustments included with the “Concentra Discontinued Operations” column of the unaudited pro forma condensed consolidated financial information is the current estimates on a discontinued operations basis and could change as our finalized discontinued operations accounting to be reported in future periods once the Separation occurs.

 

The preliminary financial data included in this offering memorandum has been prepared by, and is the responsibility of, Select’s management. PricewaterhouseCoopers LLP has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, PricewaterhouseCoopers LLP does not express an opinion or any other form of assurance with respect thereto.

 

 

 

 

Unaudited Pro Forma Condensed Consolidated Statement of Operations

For the Nine Months Ended September 30, 2024

(in thousands, except per share data)

 

  

Select Medical Holdings
Corporation Historical

(As Reported)

   Concentra Discontinued
Operations
(Note a)
   Continuing
Operations
   Transaction
Accounting
Adjustments
   Refinancing
Transactions Impact
   Pro Forma Select
Medical Holdings
Corporation
 
Revenue  $5,309,692   $(1,435,151)  $3,874,541   $   $       —   $3,874,541 
Costs and expenses:                              
Cost of services, exclusive of depreciation and amortization   4,516,553    (1,136,622)   3,379,931            3,379,931 
General and administrative   145,672    (1,569)   144,103            144,103 
Depreciation and amortization   158,151    (51,568)   106,583            106,583 
Total costs and expenses   4,820,376    (1,189,759)   3,630,617            3,630,617 
Other operating income   3,584    (284)   3,300            3,300 
Income from operations   492,900    (245,676)   247,224            247,224 
Other income and expense:                              
Loss on early retirement of debt   (10,939)       (10,939)   10,939(b)        
Equity in earnings of unconsolidated subsidiaries   49,805    3,676    53,481            53,481 
Interest expense   (143,309)   43,255    (100,054)   35,965(b)   815(d)   (63,274)
Income before income taxes   388,457    (198,745)   189,712    46,904    815    237,431 
Income tax expense   95,509    (46,241)   49,268    12,444(c)   216(e)   61,928 
Net income   292,948    (152,504)   140,444    34,460    599    175,503 
Less: Net income attributable to non-controlling interests   62,860    (11,554)   51,306            51,306 
Net income attributable to Select Medical Holdings Corporation  $230,088   $(140,950)  $89,138   $34,460   $599   $124,197 
Earnings per common share:                              
Basic and diluted  $1.78                       $0.96 
Weighted average shares outstanding                              
Basic and diluted   129,192                        129,192 

 

See accompanying notes to Unaudited Pro Forma Condensed Consolidated Financial Information

 

 

 

 

Unaudited Pro Forma Condensed Consolidated Statement of Operations

For the Year Ended December 31, 2023

(in thousands, except per share data)

 

  

Select Medical Holdings
Corporation Historical

(As Reported)

   Concentra Discontinued
Operations
(Note a)
  

Continuing

Operations

   Transaction
Accounting
Adjustments
   Refinancing
Transactions
Impact
   Pro Forma Select
Medical Holdings
Corporation
 
Revenue  $6,664,058   $(1,838,081)  $4,825,977   $   $   $4,825,977 
Costs and expenses:                              
Cost of services, exclusive of depreciation and amortization   5,732,017    (1,477,648)   4,254,369            4,254,369 
General and administrative   170,193        170,193            170,193 
Depreciation and amortization   208,742    (73,051)   135,691            135,691 
Total costs and expenses   6,110,952    (1,550,699)   4,560,253            4,560,253 
Other operating income   1,768    (250)   1,518              1,518 
Income from operations   554,874    (287,632)   267,242            267,242 
Other income and expense:                              
Loss on early retirement of debt   (14,692)       (14,692)   (10,939)(b)   (9,722)(d)   (35,353)
Equity in earnings of unconsolidated subsidiaries   40,813    526    41,339            41,339 
Interest (expense) income   (198,639)   44,474    (154,165)   169,668(b)   2,951(d)   18,454 
Income before income taxes   382,356    (242,632)   139,724    158,729    (6,771)   291,682 
Income tax expense   82,625    (53,372)   29,253    42,111(c)   (1,796)(e)   69,568 
Net income   299,731    (189,260)   110,471    116,618    (4,975)   222,114 
Less: Net income attributable to non-controlling interests   56,240    (4,796)   51,444            51,444 
Net income attributable to Select Medical Holdings Corporation  $243,491   $(184,464)  $59,027   $116,618   $(4,975)  $170,670 
Earnings per share:                              
Basic and diluted  $1.91                       $1.34 
Weighted average shares outstanding                              
Basic and diluted   127,706                        127,706 

 

See accompanying notes to Unaudited Pro Forma Condensed Consolidated Financial Information

 

 

 

 

Unaudited Pro Forma Condensed Consolidated Balance Sheet

As of September 30, 2024

(in thousands)

 

   Select Medical Holdings
Corporation Historical
(As Reported)
   Concentra Discontinued
Operations
(Note a)
   Refinancing Transaction
Adjustments
   Pro Forma Select Medical
Holdings Corporation
 
ASSETS                    
Current Assets:                    
Cash and cash equivalents  $191,468   $(136,822)  $(27,324)(d)  $27,322 
Accounts receivable   1,060,007    (232,202)       827,805 
Prepaid income taxes   8,669    (1,505)       7,164 
Other current assets   144,053    (23,041)       121,012 
Total Current Assets   1,404,197    (393,570)   (27,324)   983,303 
Operating lease right-of-use assets   1,321,045    (430,133)       890,912 
Property and equipment, net   1,040,383    (191,099)       849,284 
Goodwill   3,555,022    (1,234,707)       2,320,315 
Identifiable intangible assets, net   312,565    (209,171)       103,394 
Other assets   369,449    (5,975)       363,474 
Total Assets  $8,002,661   $(2,464,655)  $(27,324)  $5,510,682 
LIABILITIES AND EQUITY                    
Current Liabilities:                    
Overdrafts  $14,173   $   $   $14,173 
Current operating lease liabilities   249,832    (74,411)       175,421 
Current portion of long-term debt and notes payable   42,785    (9,737)   7,500(d)   40,548 
Accounts payable   170,711    (21,030)       149,681 
Accrued and other liabilities   768,203    (147,956)       620,247 
Total Current Liabilities   1,245,704    (253,134)   7,500    1,000,070 
Non-current operating lease liabilities   1,163,406    (391,037)       772,369 
Long-term debt, net of current portion   3,098,957    (1,472,610)   (34,824)(d)   1,591,523 
Non-current deferred tax liability   95,557    (22,454)       73,103 
Other non-current liabilities   98,593    (24,188)       74,405 
Total Liabilities   5,702,217    (2,163,423)   (27,324)   3,511,470 
Redeemable non-controlling interests   30,455    (18,122)       12,333 
Stockholders’ Equity:                    
Common stock   130            130 
Capital in excess of par   858,741            858,741 
Retained earnings   1,056,320    (227,064)       829,256 
Total Stockholders’ Equity   1,915,191    (227,064)       1,688,127 
Non-controlling interests   354,798    (56,046)       298,752 
Total Equity   2,269,989    (283,110)       1,986,879 
Total Liabilities and Equity  $8,002,661   $(2,464,655)  $(27,324)  $5,510,682 

 

See accompanying notes to Unaudited Pro Forma Condensed Consolidated Financial Information

 

 

 

 

Notes to Unaudited Pro Forma Condensed Consolidated Financial Information

 

Concentra Discontinued Operations:

 

(a)Reflects the anticipated discontinued operations of Concentra, including associated assets, liabilities, and equity and results of operations in accordance with ASC 205-20, Presentation of Financial Statements - Discontinued Operations as currently estimated.

 

Transaction Accounting Adjustments:

 

(b)Reflects the estimated reduced interest expense of $82.0 million for the nine months ended September 30, 2024 and $123.7 million for the year ended December 31, 2023, respectively, as a result of the payments made with the cash proceeds received in connection with the Concentra Separation to reduce long-term debt obligations. Additionally, the estimated reduced interest expense for the year-ended December 31, 2023 reflects a reclassification of a $46.0 million gain on the interest rate cap cash flow hedge from accumulated other comprehensive income into interest expense for forecasted transactions that were probable not to occur as of that date, which was reported in the historical results for the nine months ended September 30, 2024.

 

As a result of the repayments, a loss on extinguishment of debt related to the write-off of unamortized deferred financing fees of $10.9 million for the year ended December 31, 2023 is also reflected, which was reported in the historical results for the nine months ended September 30, 2024.

 

(c)Reflects the tax effects of the Transaction Accounting Adjustments to pre-tax book income at the applicable statutory income tax rates.

 

Refinancing Transaction Adjustments:

 

(d)Reflects the impacts of the Refinancing Transactions, which include the estimated reduced interest expense of $0.8 million for the nine months ended September 30, 2024 and $2.9 million for the year ended December 31, 2023, respectively, as a result of lower interest rates on the refinanced debt. With respect to the Refinancing Transactions, the pro forma financial information includes the following assumptions:

 

·Refinancing Term Loans in an aggregate principal amount of $750.0 million bearing interest at a rate equal to SOFR + 2.00% and an original issue discount of $1.9 million;
·$850.0 million of Senior Notes due 2032 bearing interest at a rate equal to 6.25%; and
·Estimated debt issuance costs of $24.3 million.

 

The net proceeds of this offering, together with the proceeds from the Refinancing Term Loans and $27.3 million of cash on hand, will be used to repay in full the Existing Select Term Loan, to redeem all of the 2026 Notes (including an estimated call premium of $12.8 million) and to pay fees and expenses related to the foregoing. The Refinancing Transactions are assumed to qualify for debt extinguishment accounting resulting in a $9.7 million loss on early retirement of debt (inclusive of the $12.8 million call premium noted above) and the capitalization of new debt issuance costs.

 

A variance of 1/8% of the weighted average interest rate estimate would result in a $2.0 million change in annual cash interest expense associated with the $1,600.0 million of indebtedness expected to be incurred.

 

(e)Reflects the tax effects of the Refinancing Transaction Adjustments to pre-tax book income at the applicable statutory income tax rates.

 

 

 

EX-99.2 3 tm2428673d1_ex99-2.htm EXHIBIT 99.2

 

Exhibit 99.2

 

 

FOR IMMEDIATE RELEASE

4714 Gettysburg Road

Mechanicsburg, PA 17055

NYSE Symbol: SEM

 

Select Medical Holdings Corporation Announces

Offering of $850 Million of Senior Notes by Select Medical Corporation

 

MECHANICSBURG, PENNSYLVANIA – November 18, 2024 – Select Medical Holdings Corporation (“Holdings”) (NYSE: SEM), today announced that Select Medical Corporation (“Select”) has commenced a private offering (the “Offering”), subject to market and other customary conditions, of $850 million in aggregate principal amount of senior notes due 2032 (the “notes”). The notes will be senior unsecured obligations of Select and will be guaranteed by certain of Select’s existing and future domestic subsidiaries.

 

Concurrently with the consummation of the Offering, Select intends to amend its existing senior secured credit agreement to, among other things, establish a new incremental term loan which will refinance Select’s existing term loans, extend the maturity date of Select’s existing revolving credit facility, and provide for an incremental revolving commitment.

 

Select intends to use the net proceeds of the Offering, together with the proceeds from the proposed new incremental term loan and cash on hand, to repay in full the term loans currently outstanding under Select’s existing senior secured credit agreement, to redeem all of Select’s outstanding 6.250% senior notes due 2026 and to pay fees and expenses related to the foregoing.

 

The notes and related guarantees have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”) or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. Accordingly, the notes and related guarantees are being offered and sold only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act and to certain non “U.S. persons” in transactions outside the United States in compliance with Regulation S under the Securities Act.

 

This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of, the notes in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offer of the notes will be made only by means of a private offering memorandum. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act. This press release shall not constitute a notice of redemption with respect to the 6.250% senior notes due 2026.

 

 

 

  

Cautionary Statement Regarding Forward-Looking Statements

 

This release contains forward-looking statements. Forward-looking statements use words such as “expect,” “anticipate,” “outlook,” “intend,” “plan,” “confident,” “believe,” “will,” “should,” “would,” “potential,” “positioning,” “proposed,” “planned,” “objective,” “likely,” “could,” “may,” and words of similar meaning, as well as other words or expressions referencing future events, conditions or circumstances. Statements that describe or relate to Holdings’ plans, goals, intentions, strategies, financial outlook, Holdings’ expectations regarding the aggregate principal amount of the notes to be sold or the intended use of proceeds from the offering of the notes, and statements that do not relate to historical or current fact, are examples of forward-looking statements. Forward-looking statements are based on our current beliefs, expectations and assumptions, which may not prove to be accurate, and involve a number of known and unknown risks and uncertainties, many of which are out of the Holdings’ control. Forward-looking statements are not guarantees of future performance and there are a number of important factors that could cause actual outcomes and results to differ materially from the results contemplated by such forward-looking statements. Additional information concerning these and other factors can be found in Holdings’ filings with the U.S. Securities and Exchange Commission, including Holdings’ most recent annual report on Form 10-K, most recent quarterly report on Form 10-Q and current reports on Form 8-K. Any forward-looking statement speaks only as of the date on which it is made. Holdings does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Investor inquiries:

Joel T. Veit

Senior Vice President and Treasurer

717-972-1100

ir@selectmedicalcorp.com

 

SOURCE: Select Medical Holdings Corporation

 

 

EX-101.SCH 4 sem-20241118.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 sem-20241118_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 sem-20241118_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 tm2428673d1_ex99-2img002.jpg GRAPHIC begin 644 tm2428673d1_ex99-2img002.jpg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end GRAPHIC 8 tm2428673d1_ex99-2img001.jpg GRAPHIC begin 644 tm2428673d1_ex99-2img001.jpg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

?WV!?X,C?%5/JR%H83>>+]*T&2&VDLM=UC2\8M]+N;F:Z52#N26WGW #:3\<:;HV ML:MJ,&E:+H&NZA=W=VUG#IVG6&H:VUU*L$,R2QZ?:_N[0LL\<)1OWBM$6/#+ M7/#,\+*$7/XVO>];M/\ )'MULKS>%6<5D;I)-6IW7N)QBTM_[U_^WC(J&X_X M][C_ '4_] N:_2'X*?\ !*3]N?XZ6EOJ7ACX.7_AC2+TJL>O?$#5[GPYI2!P MA,L377[V+=&\>VV7Y (+:Y MT:Y%Y87NE7SZIIMO>177_+!Q=;)_W%3&TIQ_P\\%^<6?Z"O_ 3VVC]BO]FMR3\GPO\ ##M#$ 9K@I; MQ!AD-Y4+9D],D]^#\8_\%)_^"2OP]_;+67XD>!;O2O ?Q]LK=O.\07D+R>&O M'EK"]U-;:;XIEC#MITEM-=W'V2^11\Y1 O[O-?7O[!FHV.B_L+_L^ZUJM[!: M6&D?!K1-8NIIONP:?I>D)=WUR>0<6L \SUR?2OIOX<_$OP/\7?!VB_$/X=:_ M;^*_"/B:&:YTG4K'!M=0CM;J>PGN)#M!\V.YM)K=A@?NX(^*_,<8I+%XA3^- M5IJ7^*ZO^)_:.42<\KR^4J7L92PE%NE_S[?*UR_@G_V\?YVW[0O[&'[2_P"S M#J=WI?Q0^&6H6&E6(:*3QS96VH:UX;U*U^U74:7$?B*U_=O+OBD6.-OWD=JM MJY^5TJ']F+]L7]H3]DSQGI?C+X2?$+4+#1UO[9M6\':QJ=SK/A#Q#;18)C&C MW?[S3-3OU464FK+\C06UK"/FMVK_ $9?%/@GPMXYT2\\/^,/#V@^(=!OD\F^ MT?5=,74[*[BE5U:WNX2#L0=0Y!"EF)X!S_*;_P %>/\ @DMX,^#_ (7UO]IG M]G73&TOPYHC7-]\1_A>H-WI,=G?.RV^J>&T(S9)&^U$LR/W;6K2?\MA7,>B? MN-^Q+^W_ /#O]KC]G6[^+L*Q^&/$/@;3=:?XJ>$&9]\L=T;-V_Y] M[2 =J^6?V0M:TO3?VI?V>->U$0_V3%\3_"C:E*/];<275^[//]&U!KE,^J'% M ']:GP[_ &__ (L_#?P+X3\$>'_^":_[0=MH?A3PMH&AV=GHVJ>"8[-+33[2 M.WW%4Z7$\Z2W$V_YR\V&Z#/@O[:7[:/[;/[1GP5\7_!GX8?\$^/BYX(L_'-@ M= \1^)/&5WX>UJ5/#&HRVD-[;Z;IEGIS16WNDB:.21%ND2ZM!+!YA_>*-C*W.%*+'M7C!RQ/(J[("(L7#RR8(\QHH_*7= MCNO<[=N&[@CTH _B_P#^"2O[/_[;_P"SI^V)X(UC6?@7\2/"/@37AJ_A?XC7 M&K"U.D?V'8W B&/1E/A12A7_9"X4XZL#[U_;\X._/F7JJ(?G QY7V?>,$]M MVXR X[ ?C_#[_P %[$!_;[\1.K!HQ\.?AT(B#G$?_"(Q8S[D[CSV(H _>+]D M'XZ67[.'_!'_ .%_QAU=+4P^"OA3JNK:=%=@&/4-;CU?6%TFV'&0UK=E;DC@ M-O'4KQ_++^SK\2_B#\8?VVO#/QN\=?#;Q'^T;XU;Q>?B'XF\"Z1_9\=[?V2+Q'J69%M M];\+!?*DD;R56>ZP\4$:JL0C4"-"C,HW.U?D%_P4K\:?M\_MXW/@?2=&_8E^ M(WPW\%^!#JM[I%EJ$WAS7=;U?7=5FMK;>=3M-6L([9)+);>);-H6>*2&2/R/."@#9'V;U M-+JU6_U/6-8BT\1^';);6^OXULI=??5+B$-,CBX6ZS&%VN_Y\_\ !+7X:^(/ MV[/V_6^(?Q^U6_\ 'S>%A)\3O%;ZXGVK3M5U6UOKN[T?28)!AA%X>2:TTY(P MJS<_\N>G/J4*>H^:RS^/? MI7PC_P &X.L:1;_&GX]:-=SVL7B"X^''AZWTF.0@3RQ:??W$3S+DC]VT4)4# MJ2C@=J /ZZQI<20E+;;;6X,6R-(_+14+9A6-0 -L=N88<_WHBN.,#\[_ /@H M]_P3]\(?MT?"R7PLNH1>$OBCX9\[5O /Q", D;1KF.$M_9]X>OV*:[>&0(,D M-+,V,;B/T@DP2K+]UD0CW&T#C\01[D$]*CVO(=@DE1,;F$8XSZD^O'3].: / MC_\ 8X_9GD_9,_9:\ _!!M7M=IQ1>5;7/B'4;2:[U^2T3C_1Y M=7EO)\X'[R63C )K^"/X6JR_MB^"97";I?VCO"EN/+^[@?$BQ8'Z_.3] ,< MU_I)ZA(@T^_".[@6&HJ3)U#+9RL1WXZ'ZDU_F\?"^+_C,KX?)_ST_:2\,S?G M\1=.7'/KLS_2@#_2"ALYC:PB";[.ZQQ@R]AZGT)X(YXZ8I]% ',:Y MH&D:U87>DZOHL.KZ5?0M%=:=.!+:7@E#(\.H0.I1[0KM/S!@6,@*D<'X%\=_ M\$JOV!?B3@2>)]#1V)D=D@71]5TW279Y'=S-- \ M[,^UF$$<*K^D!91U8#ZD#^='!'8C\Q6\*^)@DH7Y4K1U=K:]'IO?I_D<>)RW M+\:FL9EJK*3O*J[>_P!Y=ULE?R/Y\?C!_P &\/[(/CS3YY?AEKWQ$^#NN8+V M:V.JVOB'1%N,R.7U&QU2'4+F6WP4C:-=<@C*1KMM8Y#)--0_8Y_X('?##]G# MXOZ;\6?B-\1I?C?/X>C-UX4\-3^#K7PQX@_(4M=<,\QM*A4PBDU&HG%JRZWVENM^U]^IX<>" M^&*>+ACJ&3Q]M":FWK;F5M6F_):;?IPDFA6>IV,OA^]T?3=0T>XM5LYXKVS6 M>SOK)"[K;?89@;-[>,O+!'H[Y6**/[06VW!"\9X8^ ?P4\*ZE)K'AOX.?#SP M_J4DOGR7FF^"?"-EW8'H**\R/,HKG7 MO_:ZV;;?ZGOXC"X/$5*4_9>R5#E4:?\ S[4;67KHO+716LC(N4BV(KGRX83* MHQ$\"Q++:RQ[$C?(")M!'E_N^2%Y!K^!;_@N/\2;?X@?M_?$?3+&83V_P_\ MAWX:\!RL+CRMLUA'KFO.FWN0GB*-MW^UCM7]YWC[Q/8>"?"/B3Q?JD@ATWPU MHFHZS?OQ_P >=A:7$]S^:HG.>WO7^8K^T'\2;GXP?&;XM?$N\E^V7GCCQ_X@ MUR&7GY-$6ZO--TZ(COM@T_=[;^]?5\,8/VF*JXK_ )]82H_NC)GX]XOYK3I4 MU7<]M^S%;SJOVG_7+#X[T\N09;&"6"Y) K\M/^""G[:WAN?PAK?[)/CS6K?1_$N@>*-4\0_#=[R7S; M?6O#6KZIK'V_PJKG@3:?>VU]J6TY &I*3P2*_9C]A/1M(\2?L(_ 71=7B#Z1 MK/PAT70[ZW)V&YL+[31!<6T,KCXB_L MD?'/7/A3K5OKLFM:)X;\2,MW:>&-1N)VO9%TO6 I[6M6J+[=2;_ /)I)_C%GZKD<9PR;+(U/C6"H*?KRR?ZH_I:BGC6.-)9 MD$C1Q._EY$?S1H8Q&.FP1>6 1P2"F7 MR$.R:I31")9(PBH[9'JGP1_P $-_V(-6USX._&CXR? M$W2KC2=)^,GA.X^&O@:6XL1'++H!LE?7_$Q!($FCSW&I?V9"DVN@^'M-@@L-'T73K$1Z5 MIFGVFTI:Z7$.$LE&O'_AG_B7^)]*=6D=+%S_ &>QU72;>6:YNO[*.IP@RWEPXCB,ADF /E[_ M ()9?\%*_AQ^T]\+O#/@OQWXET[PO\<_ FCV?AKQ'H.NW"0+XAL[&*W?3=:T M928P9;FTNX[0G+NQL6 4_=K]F'E3RV964Q 1&+$AY24 [+BX)/E@9,A3)PCJ M23G _CH\:_\ !O=^U1X+\13W7P5^,7P_UFSL-0-SX?U.[B\0?#?Q&MFQ5HVU M&ZTI/$=L]ZCJQDE:[MI7R%:QB18YKCZ1^&__ 23_P""DFO>7I'QI_;P\0>" M?!D,,4=WI7@CQ/XC\1:C+IS@(UO_ &S=W.@OIJR*DT5E<+:2JLZ2-]I&M3/C;XB:JL\^K:9X/ U32_ VEJ\D2ZCXSO5)2V^ MT7%M=0V]LI+(\2R$+Y@K^1?_ (+QR0O^WSXBD0_NX/AWX"9PS;I49/",:$3Y M)VRE4#*/^>+1, N_ _I TW]A7Q%^S5\#K[PQ^PUJ'A+PG\;-KZC_PD8:>\E$4)B0$*D!5FSN!'Y*?%S_@AA^V1^T!X MYUSXM?&?]JOX<:SX[US^R+V^N[3X>:S!9O=:9;;-*LK0#Q)\\$ EF(?KOD=# MRAH ^UO@!\!X/VI?^")_@;X/V#R0:QKGPIU#5/#UTD'FR6?B72M9UJYT>ZL# MQB^BG1QCJ$DC.,'G^1KX6^-OB'^RG\=?"?C:'3KCPO\ $[X/^.;=+K1=6B\N M2TO=-NC;^(M!UE<\BUT^K$]//M'':OZZOV,/V)O\ @H[^R1?>"/ 5E^T1 M\&O&O[/>D:H\^I^'-3\!ZQ'KEGI4]P+O7$TB<^)?E:;J%_\ "SXT7 C>7QIH]C'+H&J7(601OXRT*ZN+N_E$MJR) M#=VL\,"B.&-;<2)*S 'V1^R'^V1\&_VO/AKX?\$SR&[@DQM:*Z";LIQ]0>)=:T7PWIDZ'IL$G6-HS(MO UW/)A)#&9YFVEUR6!W(=KC^/BQ_X(5_M[_"GQ#<:E\'/ MC'X)L!:RB'2_%6A>,?%O@C6I8RQ%XIH9)OAQX%\1ZHFG:D8C')-::GJFJJUQ>:/=J M7MM06,&%X4.TJ[.0 ?07[:.F^"?^"FG['_QQ\#? 4ZUXKU?X6Z_]C\&^)[G2 MO)\.^.O$WA&&UFU'1_"6SD7C&!_)A^QU^TEXL_8N_: M6\/_ !:LM&U!+KPMJ+Z1XZ\-7,7E7]UH=Q=R#QMI,"'K!OA3X1T7P'\//">C^$_!_AVVBL-"\.^'1]BTRPTV) WV.V@7;_;44 MDAEN9T=6:2YGG1B7)<_EQ^VW_P $=_V?/VN=4N_B)X=O[_X+_%2;)7Q-X:MR M^B:A>-YTBR^)/"NU4CDEEG=;F@2W4A0BY /T/^ /[3'P9_:6\#Z/XW^$G MBW2?$NEZG:0WDFEQWRP:_HDDMO!RE$\N#RYBRE@I+!FQG-?R#:!_P M0Z_X*(?!C7YKGX+?'[PMI4KR,TGB#PSXCU#P3_:,"2,ZR2Z7:_NYY#%Y9ED; MYY,+ WRPK7W7\+O^"27[4?Q(N;1OVV_VS_&?C[P4HAFA^&O@*ZNM-L+\P,#- M8>,-6NLR7VGWFV2WE9,JZ( "6- '[J>#/BCX!^+G@V[\7_#?Q3I_C7P]>C7 M+'3M5AN[>2(S D%EVAGV9/^='X?U.W\(?M7:) MK>IA--MO#?QTL]4U6ZNI_*$":/XOMM9,^W'*XB R>ZD=J_T7?AS\//!GP@\$ M^'? /PY\-Z3X*\)>'K1=-T7P_8#.GVC[%A@@GE'S7$-\XF=K@H27?BOX?^,;S4-(TZQU'5Y'COI]& MU6UMM8C6QDNHE>&V;1!(MR+E_MS*XC@ /Z38/%OAJ7PQ;>*SKFCKX<72H=5? M79-6&G:=;V26RO-=7U\9%3R\+CRWZ;,OC<"(=#^('A/Q/I-EKWA?Q#%K6@:E M$9]-U32(UO=-O85D>)YK2Z Q/%YT&_AQX2\/\ @/P7H$/AKPKX4TNVT30]"TS3FNK'3;"R M3RXX+>X=0TJE@TKLP!\R1P0",4 >DT444 %%%% !1110 9&<=\9_"F2?,IC_ M .>GR9]*9*0I!/I_C7.>(]2L]*TJ^U;4M1ATS2])T^]U*]OY9EB.G"UC61;P M@]5$:S@YSD*54%CBKI4_;2<.S4>^NEEZZ[&%;GHT*V*K->QI)RBK_92O^C/R M(_X+?_M+1_ 7]C3Q%X2T[4&L_%OQEN'\":$V5*0V%NL=YK\V/O!IK.ZAMO[K M!O45_!);M]FM$MROEO\ 9KYGAQ_J&:U_M MD?M0:I#X=O2_P@^#JWGA3X>V\4OFP>(-4NWN1K/C%VZA[RZGDTPKGA=(4]Z_ M+>8 1L 8FQ:WB,T71GBL!$Q;_:W1D'V -?HN28;ZKE6,I?\ /ZG+\4_P/Y/X MYX@IY_QA@XT_@R[%QIP](.D_Q[L[> %Y_[.VM MN0;!LQ7ZS?\ !/7Y_P!B?]FA/^J5>%A^>G1G'^?6ORR_X*5?LZV/[6G[;GPQ M^!&I>:6A_91^*?C3PL]O@"U\:+XK6VT0:C_T[:K)I2Z18X_Y>KB?%?G=6G[& MK4I?R3E'\6__ &X_J3)JOMLIRZK_ ,_,)2E_Z5'_ -M/W]\+^(=*\4:%H_BO M1KF/4-#\0Z5I^K:88A&!]EU"TANHF*)''M;;+@B0RR#.3*1A%YCXG^--"^&W M@KQ+\0/$^HV>EZ'X/TC4/$][=7T)EMY+;2K.XF6P8P9NP4F,;@1JRYFR%/[S M'XN_\$1OVI=9\9?"KQ+^R;\5[DP_%C]FN\7P_;MJ,PBO+SP;;W&HI3V+>/K.W^)7[06 MJVTJRR:#\&]*O;RRTS3+UDZ7?CF]M+^)E8*_D1P,=V0S9GIGS7_P3_\ V]_V MY?V]/&?Q$M/"TOP \*?#?X<>*A:>)+O7/"WQ#\1:_K.@:YJ6K7FB6OAVV.M: M/I^F:B=+M(V&IO!KO+A?[+"PJ\GL'_!3K]M']LK]AV32_BCX&A^"'B;X->,M M2L]%T/1]>\)^-9_%VC7*>'[*:XU.]N-(\;Z1;RVCZI?SA&ETK3[D&.1);942 M*23Y=_X( :7;:)\3OV[_ M86\]IIOA?XCZ9H6E6]Q_K(=+\/Z[KNAZ?$/\ M8AM=-BB'3F,U[1_P<+(A_9<^%#RHK1R_%&Q@?>N/-6Y2U#PP-_:EAON"+<;8 M=D@;TZQU/PC\2XKZ^L M=>T6TOY+668>,KXI?-'- I!F4-\I,7)=]O\ 8Y_:,_:[^-OA3]IGP-\5?"/P MS\(?M%_!'QZ?".B6_P#9/BMOA[J4<>C:#K&EWUR;WQ$=6$4YUJ6/;:LL 2)" M"TAG%?.FG?\ !5SX?_#']E+P8FB?"'X]7?BKPK\$/ NFZ-=W_P *=O@XZYX= M\&Z5'#J5SJ!\2$W.D0L\80_;K_$T6I0W-L\OG)DPA?*&S NV0G*1_:OB[Q#_P5[^&6F3>*K;PO^R7\;H; M.,7,GA_1K7XD> _$MQ8B,7$RZ9/<>+M;LYM6N2TT DDM'9E6&)UQ$M?G_P#L M0A1_P7,_:S*(41K#Q(R$Q^5O4V-L-X7N"05W=RI':OZ>2JNL8."3:K#AH?-6 M-KJ*W6*5CQQOAVD9/N!D$@'Y0_LB_P#!4CX=_M-^,-4^"_B[P5K'P'_:%T&9 M]/NOACXIU*6^M;[6X859H[*_.G:%>726MPYNE@6;_5D,MRTLA\KXK_:__;K_ M ."B'[)/QQ^%WP;N9/V;_&#/&UK&MD?%&H:9'O'^O7.E M"74;2/8MYK^@Z\EO+-(#RTU]IK6=H['YB(%.3U/5?\%;M>B\4_M@_P#!-#Q- M!;O:0>(=-\':S!;2'+16VH>*Y+FU'L'M9(90.H#\\YH _>+2?B/XL^ _P*U# MQ[^V'XY^'4-_H4&KW^O>(_!NCZGX?\-;=4GFU'1K.RL]6UO7Y]5U! ]Q;VL< M=W'$[>6J6Z2*\TOP5\/_ -K_ /;8_;BBO?$O[&_@#P%\'?@1]H>'1/CE\>=) MU'Q'K_BJVL9FT^^N]-\&6>LZ)'#YL\3FT9KN,E5)9PJJ1\8?\'#_ ,1M?O/$ M'[.W[/T5[):^$_&=U;>(?$$(G CODDUS5M.>![?K(1%I2?-G&'V@<'/]'?PC M^'VB?"OX:^"OA_X>LHK#2O"OAS2-&MX(H/LX;^S["WLVE=?XW?R!F3NH4?PT M ?EI\0O!_P#P5Q^%VB:EXR\)_''X!?&J?2[&741X!U/X8:SX#N-26Q\MYH]+ MO1\1?$F+IDNV$9-W:!E5$%C&P\ZY^D_^"=W[4'BO]KG]GC1?BC\2?#^D^$?B M%9>(/%GAGQ=X:T8W]J6:6M_N4;/+N JX*-CYG_:E\5^!/C_\ \% O@]^SIXV\ M1Z5IGPN_9MT"3XL>.].\2ZM86&E^)/&T^F7?_")V:0W?[QY]+!M[TRK^[;SE M48*,*^)?^"3?B_2_V8_^"@/[4'[%EOXBTO6_AYXNUO6?$?PJOX[VUU#2]32P ME^UV4%K+:#RP8-%73[982/,41JW1UH _HF^,VG_&34?!>H_\*$\0>!]'^(J2 M0/IVK>/M$U'7=#CD#S:;,IM=-U73[B.:YMQ'#YJ1$C )D8J$C_"G]F#]NS_@ MHQ^TI^TG\4?V==+L?V<_"&J_!,O$KZ!X^OH18Z-JMGHMRVBZ/JOBO2( M+>^U"]L[7YO[;:!%=";!?F'7EB? M8?S-?\$M/^4I/_!0W_L)>/?_ %.;J@#^F+2X9(5Q,(_,<([&*..&)V\F-&EB M@26Y,$4KHTB127E[(JL"URX*JFD_WC^'\A2-U/U/\Z2@ HHHH **** "BBB@ M#X?_ &X?VZ?A/^PIX(\.^-OBI%XCNXO%^M/H'AO3O#.F?VA?7^J6MG9@E=S,,_VIXT\2Z%$CF_T^28?)IEI)$]OC3POF1S&>>1W\]X,S76DZD'5XH(E#*4VXY1N_Y MZ1?\&['[ J[D27XQJH=C\GCZSAR7_>,SK#X:1'_:)[S;/?B2=+=HTCM1/\ W)FMH8I&0]%<>I-1RR1RPR/Y M=N\AL[_+)+YL@(MY1@-V'^R.F2>^:_N9?_@W?_8*C)"WGQG10,D?\)UITY)[ MG=<>&7<< ?*&"Y&0 2289/\ @WD_8&5]LES\:9"\%RN?^$XTE4*8B.V2'_A% M2CA3\P!(+9*E@ #7O3XEP-2%>C",N17C#W7MRIZZ:;O<_,L-X2\686M6Q52M M1=&IF,*D%[6%^5^Q3TYM/>C/3T/T(_X)[.S?L3_LTP-#(K_\*B\/,7DQD))I M#@#OP"I(YZ$8'.:^-3X@LO$'_!;JSTB.Y@4^%_V/+73Y%N #'=/=>+M0FDM8 MQR#-AMP!ZF0<8XK]0?AW\'?"OPO^#VC_ 2\+76O6OA7PKX8@\*Z7>'4HH]< MLM.:.2.&[M+^SL;18]1@EEEDCE\A3D1[I& *#X"T_P#X)!? .V\>W7Q4M_BY M^TN/B<&NX+SQT/BJ4UV\L[B47\>C/V\0P6TN M?DO[S2(?"L>$_B[^VC\7=/NX?BI^UCJ&H> M/-+T^_O/ML?P]^$FGZ5/9?#7PI#)_P LS;>&[.UUB_BZ+J^M:BW63-?;G[0' M[)OPL_:1^%.F?"SXN6^JZ_X9TC4_#NLQ7'Q9I8WMQJ/V2T62]G M:VC6_G:%FG2-""!B./JOBK\ M#^*/PVA^$W_ E'C7P!HJ#2;>WUCX<:['X; M\0VMCH5G%;6^GPWS:=>D6DUJN)X\+NFEED'.3)B=Q_/U_P $)=4MX/VGO^"@ M6@M>V]PMW\2KN^M8[?[D]O)\0/'4RW+\??,GFQ-C^&)?6O7O^#A>_"_LO?"& M)L(TGQ9TRXMV?!C1H9;99T)Y^[$BMW #'U-?7?P?_P"".W[-7P2\80?$+X:> M._C]X7\3W=^MYK=[I_Q)AB7Q8UOJ-UJ0M_%D8T C6;26XFFDDAD\L%I&YP'F^(4%OX3T.\-G:V#-I6AI MH#PVY\FSC<2"0L7;! "@D ^BO@II?A+XB_LK?"'P_JBZ?JGAGQ3\"/AQH&K: M>Q\N"^L+OP?HZ7UO;S?*1?+:KJ#NJDL%:V; )KB?"OQD^"?P(^(?P2_8@\! M65]J7BB/P!<_\(UI6AH-4_X0OP3X%M=-T/2I_$EZ>+=9[,&)[8DE(T67:!*I M/A7AW_@D3\#_ OI?_"/^$?CA^UIX7T6T6.U%AHWQNN+*W B"W")!;PZ L4- MN/.VB(9("D;B"-O0_#?_ ()1_ CX5ZI\3?%7AOQ]\=I?'OQ2\.V?AK5_B'K/ MQ+.L^,?#MC87-W=+=^$-4N] WZ1J-V;R6*ZG7*F,+L4MG(!^1G[&.OZ/8_\ M!<;]JF"74-.MS=#Q386JQ/YC/<6-I;126,6<[4,B-/M'22>0]":_J(O-7M-. MT^;5=5N[?2[*.Q>:Y>]G$=E# +>#[1<78; %O;PCS VXH2>''2[DD\I9 M)#+"-SLZDE0M>F)_P2X^%WBOR;?X@_M!_M9?$[09,QP^%?%7QK@]#BOZ M*/A5^SU\&_@)X1/@SX/^ /#OPX\-01VHELO#-EY=Q(\'F"*X;4+B1[F>_69V MG.H7+2W$C;0^1$E?GU\0/^"-O[-'Q@\97'C_ .(?C[]H;Q=XSM=9FU2SUC5_ MBI+(NF74^I1:U;P:-;RZ)>'2K729CYVF?9YB8KJXN)#& 1O /ES_ (+P_LG^ M-_B_\+O _P"T'\/=+DUOQ-\$GU&[\2Z196XEO6\)07"M4MO$%NGQ1\*^&]'\-?$WP7+C274T?6,Y^L/@S\#-*^"?PVMOAK%XR\>_$S2( M+K696U3XL:\GB[Q'=VVLWUQ>/97FKFQL3-;VPN#%;HUNQ5=Y+D, OQG\2O\ M@E+^RUXP\:'XB^!5^(?[/OQ&U&XDDN/%_P #/&E[X2N]0N"TEPTFK:=-%>Z+ M?%GF(DEGTV:>6-8H)':*&)5 /T3UW5;;0]-OM6U.^TS3=/L1%2"Z$]\.I\A(YW,BG#<#JN3\-?"+]NGX8?$_P"%_P =_BWH5G?VWPE^!/BK MQ+X0_P"$MO[H2:3XZM?!$MW8ZWJ6APG(;3FU1S80DJ=TUG.H("X;RW7O^"4] MA\0M)_X1KXP_M@_M$/AUH^LZG:7 M$1"2O<:IYTJLROPB$]?XW_X)0?LS>,_AIX2^"^G:C\5? 'P@\(:(F@1?#?P# MX_N=%\-ZM$EQ=W-/VQ_VHOAM:>/?&O[2GC_ ,6>-O##ZEJWB'0WT7X?ZCJ4:Z;8 MVUKI6KZ?;2VL>DQ074=T\+SO)=2PM(4BB$?RI_P4V_9U^'__ 3I^/\ ^RI^ MU=^SKX&C\(>$O#WB1+'Q7H^G:EJ>J6NM:A8:I:ZG/=:E/JU[?W,=LWAG9I?E M),L"_:3(L8>21W_H:_9@_9*\$?LG^$;CX?> ?%WQ(U[P@$CAT71/&_BA=>MO M"EI#@BQ\,[-/LAIFGRM'NELE1U\V6XF$I,[1KY1^U-_P3F^"_P"V-K":I\9/ M%?Q--*\<^&/#WBOPQJ5G?Z)XIT6/5M UF 6WV.YMDNQTEA8?[9 MD%?S>_\ !+K6]%3_ (*K_M]6C:E;?;M3U;X@_P!C$_\ ,2,7C>Y6Y;/^\CCU M^3BOUP^'W_!-+X;?"_X8>(OA#X&^-?[2VC^"?$/]F&VAA^*J1:IX4M+%I)!: M>&K]/#C/!#=;FBN(I5">66*DLQ%>":+_ ,$0/V2_".O3>,=#\:?M#:+XMNY9 M9KCQ+H7Q9U#1]=GEGGEG>2;4=.L;0RM))*\LI>W:1YI)"9"I14 /TY^+OQ<\ M(?!+P#XO^)_CC4K?3O"_A#2;[6=1"2@WCV=A:WES/\ PUIGBS3-+U#39/MEKIVM6ZWM M@)\0N"TMI+#."&.4E4\9P/SP\9_\$11+K%KJ&CWLEW"OGY<"90ZJ%\I3EV_4W3/"-EH>F:;HNC6 HECI^DZ1I]EI>FV45O8,EM9:?;16EO&&DTIW)$4*EB6.6)QQ@4 ?_V0$! end XML 10 R1.htm IDEA: XBRL DOCUMENT v3.24.3
Cover
Nov. 18, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 18, 2024
Entity File Number 001-34465
Entity Registrant Name SELECT MEDICAL HOLDINGS CORPORATION
Entity Central Index Key 0001320414
Entity Tax Identification Number 20-1764048
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4714 Gettysburg Road
Entity Address, Address Line Two P.O. Box 2034
Entity Address, City or Town Mechanicsburg
Entity Address, State or Province PA
Entity Address, Postal Zip Code 17055
City Area Code 717
Local Phone Number 972-1100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol SEM
Security Exchange Name NYSE
Entity Emerging Growth Company false

EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://selectmedical.com/role/Cover Cover Cover 1 false false All Reports Book All Reports sem-20241118.xsd sem-20241118_lab.xml sem-20241118_pre.xml tm2428673d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2428673d1_8k.htm": { "nsprefix": "sem", "nsuri": "http://selectmedical.com/20241118", "dts": { "schema": { "local": [ "sem-20241118.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "sem-20241118_lab.xml" ] }, "presentationLink": { "local": [ "sem-20241118_pre.xml" ] }, "inline": { "local": [ "tm2428673d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://selectmedical.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-11-18", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2428673d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-11-18", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2428673d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://selectmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 18 0001104659-24-119970-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-119970-xbrl.zip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end XML 19 tm2428673d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001320414 2024-11-18 2024-11-18 iso4217:USD shares iso4217:USD shares false 0001320414 8-K 2024-11-18 SELECT MEDICAL HOLDINGS CORPORATION DE 001-34465 20-1764048 4714 Gettysburg Road P.O. Box 2034 Mechanicsburg PA 17055 717 972-1100 Common Stock, par value $0.001 per share SEM NYSE false false false false false